NCT03325101 - Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

June 14, 2020

Study Completion Date

June 14, 2020

Conditions

Stage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

PROCEDURE

Cryosurgery

Undergo cryosurgery

BIOLOGICAL

Pembrolizumab

PROCEDURE

Pheresis

apheresis

BIOLOGICAL

Therapeutic Autologous Dendritic Cells

Intra-tumoral injection

Trial Locations (1)

55905

Mayo Clinic, Rochester